Department of Palliaitve Medicine, Marymount University Hospital and Hospice, Cork, Ireland
Department of Palliaitve Medicine, Marymount University Hospital and Hospice, Cork, Ireland.
BMJ Support Palliat Care. 2019 Sep;9(3):271-273. doi: 10.1136/bmjspcare-2018-001504. Epub 2018 Oct 9.
Extrapyramidal side effects (EPSEs) are serious potentially reversible side effects of antipsychotic and other medications that can cause distress for patients. A core principle of palliative care involves optimising quality of life. If side effects of medications are burdensome, it is imperative that we address this issue. The aim of the study was to determine and describe the burden of EPSEs in a specialist inpatient unit.
Consenting patients who met inclusion criteria were assessed for EPSE with two validated screening tests, the Modified Simpson-Angus Scale (MSAS) and Barnes Akathisia Rating Scale (BARS). Additional demographic data were collected including medications associated with EPSE, previous history of EPSE and known risk factors that may predispose a patient to EPSE.
43% inpatients met inclusion criteria. At least 66% of patients were taking regular medications associated with EPSE. Of those, 25% were taking ≥2 medications associated with EPSE. The MSAS revealed 50% scored <3, 44% scored 3-5% and 6% scored 6-11. Seven patients had at least one 'not rateable score'. In the BARS (sitting±standing), 94% scored 0/5 and 6% scored 1/5. 12.5% of participants were able to stand for 2 min to complete the BARS.
50% screened positive for EPSE. The complete BARS was unsuitable for most participants. The MSAS, while allowing a not rateable score, may underestimate EPSE. The frailty of an inpatient unit population impacts on applicability of screening tools and may therefore underestimate the burden of the problem in this population. Development of a population-specific screening tool warrants further investigation.
锥体外系副作用(EPS)是抗精神病药和其他药物的严重潜在可逆转副作用,会给患者带来痛苦。姑息治疗的核心原则是优化生活质量。如果药物的副作用是负担过重,我们必须解决这个问题。本研究的目的是确定和描述专科住院患者 EPS 的负担。
符合纳入标准的患者使用两种经过验证的筛选测试,即改良 Simpson-Angus 量表(MSAS)和 Barnes 静坐不能评定量表(BARS),评估 EPS。还收集了其他人口统计学数据,包括与 EPS 相关的药物、以前的 EPS 病史以及可能使患者易患 EPS 的已知危险因素。
43%的住院患者符合纳入标准。至少 66%的患者正在服用常规 EPS 相关药物。其中,25%的患者正在服用≥2 种与 EPS 相关的药物。MSAS 显示 50%的评分<3,44%的评分 3-5%,6%的评分 6-11。7 名患者至少有一个“无法评分”。在 BARS(坐着±站立)中,94%的评分为 0/5,6%的评分为 1/5。12.5%的参与者能够站立 2 分钟完成 BARS。
50%的患者筛查结果为 EPS 阳性。完整的 BARS 不适合大多数参与者。MSAS 虽然允许“无法评分”,但可能会低估 EPS。住院患者群体的脆弱性会影响筛选工具的适用性,因此可能会低估该人群中该问题的负担。进一步调查需要开发针对特定人群的筛查工具。